{"disease":{"id":"gliosarcoma","name":"gliosarcoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00035373","title":"Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research Protocols","phase":"","overall_status":"TERMINATED","enrollment_count":767,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02573324","title":"A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":691,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT00884741","title":"Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":637,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02152982","title":"Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":447,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05095376","title":"Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":265,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT01062425","title":"Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":261,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01730950","title":"Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":182,"lead_sponsor_name":"Radiation Therapy Oncology Group","has_results":true},{"nct_id":"NCT04396860","title":"Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":159,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03115333","title":"DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":146,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT01430351","title":"Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":144,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01609790","title":"Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":137,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06954636","title":"Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study","phase":"","overall_status":"RECRUITING","enrollment_count":128,"lead_sponsor_name":"Sied Kebir","has_results":false},{"nct_id":"NCT00731731","title":"Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00433381","title":"Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00441142","title":"Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":119,"lead_sponsor_name":"Patrick Y. Wen, MD","has_results":true},{"nct_id":"NCT00100802","title":"Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":118,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT00305864","title":"Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":118,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00329719","title":"Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":115,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01814813","title":"Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":90,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":true},{"nct_id":"NCT00268385","title":"Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":83,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01189266","title":"Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":79,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04477200","title":"Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":68,"lead_sponsor_name":"University of Michigan Rogel Cancer Center","has_results":false},{"nct_id":"NCT01514201","title":"Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02455557","title":"SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":66,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT02661282","title":"Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02386826","title":"INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"SCRI Development Innovations, LLC","has_results":false},{"nct_id":"NCT05857969","title":"Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":65,"lead_sponsor_name":"Florida International University","has_results":false},{"nct_id":"NCT00423735","title":"Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02658981","title":"Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":false},{"nct_id":"NCT03174197","title":"Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04528680","title":"Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":57,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT05465954","title":"Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02942264","title":"Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":53,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03197506","title":"Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":52,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT01149850","title":"Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT00902577","title":"MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02798406","title":"Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"DNAtrix, Inc.","has_results":false},{"nct_id":"NCT04817254","title":"Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01922076","title":"Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01614795","title":"Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02133183","title":"Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":40,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00879437","title":"Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Baylor College of Medicine","has_results":true},{"nct_id":"NCT02197169","title":"DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"DNAtrix, Inc.","has_results":false},{"nct_id":"NCT01051557","title":"Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03896568","title":"MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07301268","title":"GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02255461","title":"Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":35,"lead_sponsor_name":"Pediatric Brain Tumor Consortium","has_results":true},{"nct_id":"NCT01931098","title":"Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00102648","title":"Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":34,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01753713","title":"Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Manmeet Ahluwalia, MD","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}